RxDoctor Payments Data

Valentina Bradley, MD

MOHS-Micrographic Surgery · Ocala, FLNPI 1902898083

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,242 of the $2,625 with a category attached, or 85.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $795, more than ten times the $39 reported in 2019.

$2,625in general payments, 2019–2025

Across 118 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$606
  • Johnson & Johnson$525
  • AbbVie$248
  • Novartis$166
  • E.r. Squibb & Sons, L.L.C.$150
  • Amgen$144
  • plus $787 from 14 others

What the payments were for

  • Food & beverage$2,24285%
  • Education$38315%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,625 in reported general payments places this provider in the 60th percentile of 141 mohs-micrographic surgery providers in Florida.

See all mohs-micrographic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$494,739
Medicare patients
1,072
Services billed
5,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab12$171,127
Humira(Cf) PenAdalimumab12$162,820
OdomzoSonidegib Phosphate12$161,835
Clobetasol Propionate176$6,880
Ketoconazole205$4,316
Clindamycin Phosphate59$2,503
Fluorouracil28$2,165
Fluocinolone AcetonideFluocinolone/Shower Cap23$1,687
Doxycycline Hyclate43$1,089
ValacyclovirValacyclovir Hcl14$947
Fluocinolone Acetonide12$863
Hydroxyzine Hcl19$553
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim72$406
Betamethasone Dipropionate12$368
Mometasone Furoate20$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$248$171,12712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 141 mohs-micrographic surgery providers in Florida.

Other mohs-micrographic surgery in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →